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T h ep o s s i b l er o l eo fβ-2 adrenergic receptors in modulation of inﬂammatory and nociceptive conditions suggests that the β-2
adrenergic receptor agonist, salbutamol, may have beneﬁcial anti-inﬂammatory and analgesic eﬀects. Therefore, in this study, we
inducedinﬂammatoryandnociceptiveresponseswithcarrageenan-inducedpawedemaorcotton-pellet-inducedgranulomamod-
els, both of which result in oxidative stress. We hypothesized that salbutamol would prevent inﬂammatory and nociceptive
responses by stimulating β-2 adrenergic receptors and the prevention of generation of ROS during the acute inﬂammation process
in rats. Both doses of salbutamol used in the study (1 and 2mg/kg) eﬀectively blocked the acute inﬂammation and inﬂammatory
nociception induced by carrageenan. In the cotton-pellet-induced granuloma test, both doses of salbutamol also signiﬁcantly
decreased the weight of granuloma tissue on the cotton pellets when compared to the control. Anti-inﬂammatory and analgesic
eﬀects of salbutamol were found to be comparable with those of indomethacin. Salbutamol decreased myeloperoxidase (MPO)
activity and lipid peroxidation (LPO) level and increased the activity of superoxide dismutase (SOD) and level of glutathione
(GSH) during the acute phase of inﬂammation. In conclusion, salbutamol can decrease acute and chronic inﬂammation, possibly
through the stimulation of β-2 adrenergic receptors. This anti-inﬂammatory eﬀect may be of signiﬁcance in asthma treatment,
where inﬂammation also takes part in the etiopathology. This study reveals that salbutamol has signiﬁcant antioxidative eﬀects,
which at least partially explain its anti-inﬂammatory capabilities. These ﬁndings presented here may also shed light on the roles of
β-2 adrenergic receptors in inﬂammatory and hyperalgesic conditions.
1.Introduction
Inﬂammatory diseases such as rheumatoid arthritis, hepati-
tis, and asthma are major causes of morbidity in humans.
Chronic inﬂammation is now well known to also lead to the
development of cancer [1], cardiovascular diseases [2], and
neurodegenerative diseases [3]. In inﬂammatory diseases,
the most common complaint of the patient is accompa-
nying nociception and fever. Although nonsteroidal anti-
inﬂammatory drugs (NSAIDs), especially indomethacin, are
thedrugsofchoiceinthetreatmentofinﬂammatorydiseases
[4]andarehighlyeﬀective,theyhaveanumberofdeleterious
side eﬀects, such as gastrointestinal ulcers and even bleeding
[4, 5]. So investigators are still looking for new analgesic
drugs with fewer side eﬀects for the treatment of inﬂamma-
tion and nociception.
The most common mechanism for the anti-inﬂamma-
tory and analgesic eﬀects of NSAIDs is via the inhibition
of prostaglandin synthesis by the COX enzyme [6]. On the
other hand, some other mechanisms such as the L-arginine/
nitric oxide pathway or the serotonergic system have also
beensuggestedforanalgesiceﬀectsofNSAIDs[7,8].Inaddi-
tion,LizarragaandChambersclaimarolefortheopioidergic
system in the analgesic eﬀect mechanism of NSAIDs [9].2 Mediators of Inﬂammation
However, recent studies now claim a role for β-2 adrenergic
receptors in the anti-inﬂammatory and analgesic eﬀects of
NSAIDs [10, 11] .Ar o l ef o ra d r e n e r g i cβ-2 receptors has
been previously demonstrated in inﬂammatory conditions
[12, 13]. While there are some publications that indicate that
activation of β-2 adrenergic receptors may be involved in
the increased nociceptive sensitivity [14], and inﬂammatory
hyperalgesia[15]recentstudiessuggestedthatβ-2adrenergic
receptor activation can inhibit nociception and inﬂamma-
tion [16–18].
Recent literature on a possible role of β-2 adrenergic
receptors in modulation of inﬂammatory and nociceptive
conditions led us to hypothesize that β-2 adrenergic receptor
agonists,suchassalbutamol,mayprovideanti-inﬂammatory
and analgesic relief for nociceptive inﬂammatory conditions.
Salbutamol is a well-known drug that is commonly used in
the treatment of bronchial asthma [19]. Salbutamol selec-
tively binds to and activates β-2 adrenergic receptors on the
surface of many cells. The inhibitory eﬀect on inﬂammatory
processes is seen primarily for CD4 cells but also for other
leucocyteswithahighdensityofβ-2receptorssuchasmono-
cytes, macrophages, and Langerhans cells [20–22]. Also anti-
inﬂammatory eﬀects of β-2 adrenergic receptors on pul-
monary inﬂammation models [23] support the role of β-2
adrenergic receptors in inﬂammatory conditions.
The binding of the β-2 receptor agonist to these cells
inhibits activation of the expression of inﬂammatory genes
and thereby their proinﬂammatory cytokines, such as inter-
leukin-2 and interferon-γ. Salbutamol also inhibits super-
oxide generation and peroxidase release from stimulated
human granulocytes [24]. These eﬀects can be investigated
for their therapeutic potential using inﬂammation models.
For example, one hour after subcutaneous injection of car-
rageenan into the rat paws nociception model or inﬂam-
mation model, in which vascular permeability increases and
leukocyte migration occurs, involves inﬂammatory media-
tors including neutrophil-derived active oxygen species and
free radicals, such as hydrogen peroxide, superoxide and the
hydroxyl radical [25–27] nitric oxide, prostaglandins, and
cytokines [28]. Also, neutrophil accumulation liberated pro-
inﬂammatory mediators such as cytokines, including TNF-α
and IL-1β, are considered to be proinﬂammatory agents that
stimulate the cellular chemotaxis and serve to further in-
creasetissueinﬂammation[29].However,nostudieshaveyet
investigatedtheanti-inﬂammatoryandanalgesicpotentialof
salbutamol in relation to these oxidative parameters.
Therefore,inthepresentstudy,weinducedinﬂammatory
and nociceptive responses with carrageenan-induced paw
edema and with cotton-pellet-induced granuloma models.
Both of these treatments result in oxidative stress, and we
hypothesized that salbutamol would prevent inﬂammatory
and nociceptive responses by stimulating β-2 adrenergic
receptors and reducing the generation of reactive oxygen
species (ROS) during acute inﬂammation process in rats.
2.MaterialsandMethods
2.1. Animals. In this study, we used a total of 90 male
Albino Wistar rats obtained from the Medical Experimental
Research Centre, Atat¨ urk University (ATADEM). The ani-
mals weighed between 200 and 220g and were fed under
normal temperature conditions (22◦C) in separate groups
beforetheexperiments.Animalexperimentswereperformed
in accordance with the national guidelines for the use and
care of laboratory animals, and the study was approved by
the local animal care committee of Atat¨ urk University.
2.2. Chemicals. All chemicals for laboratory experimenta-
tion, including carrageenan, were purchased from Sigma
Chemical (Germany). Thiopental sodium was purchased
from IE Ulagay A. S. Istanbul, Turkey; indomethacin was
purchased from Deva, Turkey; salbutamol was purchased
fromGlaxoSmithKline,andpropranololwaspurchasedfrom
Sanoﬁ Aventis, Istanbul, Turkey.
2.3. Carrageenan-Induced Paw Edema in Rats. In the ﬁrst
series of experiments, the anti-inﬂammatory eﬀects of salbu-
tamol and indomethacin on carrageenan-induced paw
edema were studied in rats [30]. The rats were divided into
4g r o u p s( n = 6) for experimental procedure. Three rat
groups received salbutamol 1mg/kg, salbutamol 2mg/kg, or
indomethacin 25mg/kg by oral gavage. Rat doses of salbuta-
mol diﬀer from 3μgt o6 0m g / k g[ 31, 32]. In this study we
selected 1 and 2mg/kg doses of salbutamol [33, 34]. In acute
inﬂammation model and hyperalgesia model we studied
indomethacin at 25mg/kg dose, which has been previously
used [35–37]. The reason why we used the 25mg/kg dose in
acute experiments is that we aimed to compare the eﬀects
of salbutamol with the highest dose of the reference drug.
All drugs were suspended in distilled water as vehicle. So the
control group (4th group) received an equal volume of dis-
tilled water as vehicle. One hour after drug administration,
0.1mL of 1% carrageenan was injected into the hind paw
of each rat in each group. Before the carrageenan injection,
the normal paw volumes of the rats were measured with a
plethysmometer. The carrageenan-induced increase in the
paw volume was measured four times at one-hour intervals.
Namely, the paw volumes were measured for every 60 min-
utes times four hours after carrageenan injection [38–40].
The eﬀects of the drugs were determined by comparing the
results of the drug-treated groups with those of the control
group. At the end of the experiment, paw tissues of all
animals, as well as from an additional untreated group of
healthyanimals,werecollectedforbiochemicalexamination.
Allofthepawtissueswereimmediatelytransferredto −80◦C.
In the second series of experiments we investigated
whether anti-inﬂammatory activity of salbutamol is related
to β-2 adrenergic receptor stimulation or not. For this pur-
poseatotalof12ratsweredividedinto2groups(n = 6).The
ﬁrst rat group received 40mg/kg dose of propranolol, which
was suspended in distilled water by oral gavage. One hour
after propranolol administration the rat group received
2mg/kgdoseofsalbutamolbyoralgavage.Thecontrolgroup
(2nd group) received an equal volume of distilled water as
vehicle, and anti-inﬂammatory activities were determined as
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2.4. Carrageenan-Induced Inﬂammatory Paw Hyperalgesia in
Rats. In this series of experiments, the analgesic eﬀects of
salbutamol and indomethacin on carrageenan-induced in-
ﬂammatorypawhyperalgesiawerestudiedinintactrats[41].
The rats were divided into 4 groups (n = 6). Drug admin-
istration and carrageenan treatment were repeated exactly
as described in Section 2.3. Prior to carrageenan injection,
the normal nociceptive thresholds of the rats were measured
with a Basile algesimeter that measures mechanical reﬂex
threshold. Carrageenan-induced decrease in the nociceptive
threshold was measured three times at one-hour intervals.
Namely, the nociceptive thresholds were measured for every
60minutestimesthreetimesaftercarrageenaninjection.The
analgesic eﬀects of the drugs were determined by comparing
the results of the drug-treated groups with those of the
control group.
2.5. Cotton Pellet Granuloma Test. In this part of experiment,
we used 24 rats divided into 4 groups to examine the eﬀects
of salbutamol and indomethacin on the proliferative phase
of inﬂammation [42]. For this purpose we used the cotton
pellet test, which is a chronic inﬂammation model used for
evaluating the antiproliferative eﬀects of drugs [42, 43]. In
this model, a short time after the initiation of acute inﬂam-
mation, proliferative cells developed and inﬂammation
became chronic. Monocyte-macrophages inﬁltration and
ﬁbroblast proliferation occur in chronic inﬂammation [44].
Also in the cotton-pellet-induced chronic inﬂammation
model, cotton pellet, which we applied in interscapular area,
induced a chronic inﬂammation process. In this process
monocyte migration, liquid accumulation, apoptosis, dam-
age and so on will occur in the surrounding tissue of the
pellets and these accumulations will produce a granulation
tissue that covers the pellets. Salbutamol at 1mg/kg and
2mg/kg doses was administered to the ﬁrst two groups of
rats, and 5mg/kg of indomethacin [45]w a sg i v e no r a l l ywi t h
the aid of gavages to a third group. The reason why we used
5mg/kg dose of indomethacin in chronic administration is
that high dose (25mg/kg) indomethacin has quite harmful
eﬀects on stomach resulting in stomach bleeding and even
death in chronic administrations. All drugs were suspended
in distilled water as vehicle. The control group received an
equal volume of distilled water. Thirty minutes after the ad-
ministration of drugs, rats were anesthetized with 20mg/kg
of thiopental sodium. Cotton pellets, weighing 7±1mgand
prepared under sterile conditions, were then implanted sub-
cutaneously (sc) in the interscapular area. Drugs were ad-
ministered once a day for a period of 7 days. On the 8th day,
rats were euthanized with a high-dose (50mg/kg) of thio-
pental sodium. Cotton pellets with the granuloma tissue that
involvesmigratedmonocytes,accumulatedliquid,andﬁbro-
blasts were removed and weighed. Eﬀects of the drugs on
chronic inﬂammation were determined by comparing the
results obtained for the test groups with the results of the
control group.
2.6.BiochemicalEstimations. Afterthemacroscopicanalyses,
superoxide dismutase (SOD) and myeloperoxidase (MPO)
enzyme activities and the glutathione (GSH) and lipid per-
oxidation (LPO) levels in rat paw tissues were determined.
To prepare the tissue homogenates, whole paw tissues were
ground with liquid nitrogen in a mortar. The ground tissues
(0.5g each) were then treated with 4.5mL of appropriate
buﬀer. The mixtures were homogenized on ice using an
ultraturrax homogenizer (IKA-Germany) for 15min. Ho-
mogenates were ﬁltered and centrifuged by using a refriger-
ated centrifuge at 4◦C. Then, these supernatants were used
for determination of the enzymatic activities. All assays were
carried out at room temperature in triplicate.
2.6.1.SuperoxideDismutaseActivity. AsoutlinedbySunetal.
[46] superoxide dismutase estimation was based on the
generation of superoxide radicals produced by xanthine and
xanthine oxidase, which react with nitro blue tetrazolium
to form formazan dye. Superoxide dismutase activity was
then measured at 560nm as the degree of inhibition of this
reaction and was expressed as millimoles per minute per
milligram tissue (mmol/min/mg tissue).
2.6.2.MyeloperoxidaseActivity. Myeloperoxidaseactivitywas
measured according to a modiﬁed method of Bradley et al.
[47]. The homogenized samples were frozen and thawed
three times and centrifuged at 1500g for 10min at 4◦C.
Myeloperoxidase activity in the supernatant was determined
by adding 100mL of the supernatant to 1.9mL of 10mmol/L
phosphate buﬀer (pH 6.0) and 1mL of 1.5mmol/L o-dia-
nisidine hydrochloride containing 0.0005% (wt/vol) hydro-
gen peroxide. The changes in absorbance at 450nm for
each sample were recorded on a UV-Vis spectrophotome-
ter. Myeloperoxidase activity in tissues was expressed as
micromoles per minute per milligram tissue (μmol/min/mg
tissue).
2.6.3. Total Glutathione (GSH) Determination. The amount
of GSH in the paw tissues was measured according to the
method of Sedlak and Lindsay [48]. The paw tissue homo-
genizedin2mLof50mMTris-HClbuﬀercontaining20mM
EDTA and 0.2M sucrose, pH 7.5. The homogenate was
centrifuged at 4200rpm for 40min at 4◦C, and then the
supernatant was used to determine GSH using 5,5-di-
thiobis(2-nitrobenzoic acid). Absorbance was measured at
412nm using a spectrophotometer. The results of the GSH
level in the rat paw tissues were expressed as nanomoles per
milligram tissue (nmol/mg tissue).
2.6.4.DeterminationofLipidPeroxidationLevel. Lipidperox-
idation levels in paw tissues were determined by estimating
malondialdehyde (MDA) using the thiobarbituric acid test
[49]. Brieﬂy, the paw tissues were promptly excised and
rinsed with cold saline. To minimize the possibility of inter-
ference of hemoglobin with free radicals, any adhering blood
or bristles on the epidermis were carefully removed. The paw
tissues were weighed and homogenized in 10mL of 100g/L
K C l .T h eh o m o g e n a t e( 0 . 5 m L )w a sa d d e dt oas o l u t i o n
containing 0.2mL of 80g/L sodium lauryl sulfate, 1.5mL of
200g/Laceticacid,and1.5mLof8g/L2-thiobarbiturateand4 Mediators of Inﬂammation
Table 1: Eﬀects of salbutamol and indomethacin on carrageenan-induced inﬂammatory paw edema in rats.
Drugs Increase in inﬂammatory paw volume (mL) Anti-inﬂammatory eﬀect
1st h 2nd h 3rd h 4th h 1st h 2nd h 3rd h 4th h
SAL-1 0.14 ± 0.02∗ 0.28 ± 0.13∗ 0.27 ± 0.05∗ 0.27 ± 0.03∗ 43.9 43.4 44 37.5
SAL-2 0.13 ± 0.03∗ 0.26 ± 0.05∗ 0.25 ± 0.04∗ 0.22 ± 0.03∗ 44.6 48.1 48.5 48.8
IND-25 0.19 ± 0.01∗ 0.29 ± 0.06∗ 0.28 ± 0.02∗ 0.22 ± 0.02∗ 27.7 40.3 42.7 48.4
Control 0.25 ± 0.03 0.49 ± 0.06 0.49 ± 0.02 0.43 ± 0.02 — — — —
SAL-1: salbutamol 1mg/kg; SAL-2: salbutamol 2mg/kg; IND: indomethacin 25mg/kg. ∗Signiﬁcant at P<0.05 when compared to control. (All groups
received an intraplantar injection of 0.1mL, 1% carrageenan.)
Table 2: Eﬀects of salbutamol and indomethacin on carrageenan-induced inﬂammatory paw nociception in rats.
Drugs Decrease in nociceptive threshold (g) Analgesic eﬀect (%)
1st h 2nd h 3rd h 1st h 2nd h 3rd h
SAL-1 18.2 ± 1.3∗ 25.7 ± 2.4∗ 30.2 ± 3.3∗ 57 44.2 36.9
SAL-2 16.7 ± 2.7∗ 24.0 ± 4.8∗ 27.3 ± 4.1∗ 61.1 47.8 42.9
IND 12.2 ± 2.2∗ 20.7 ± 4.4∗ 19.8 ± 5.1∗ 71.6 55 58.5
Control 42.8 ± 5.4 46.0 ± 2.5 47.8 ± 2.7 — — —
SAL-1: salbutamol 1mg/kg; SAL-2: salbutamol 2mg/kg; IND: indomethacin 25mg/kg. ∗Signiﬁcant at P<0.05 when compared to control. (All groups
received an intraplantar injection of 0.1mL, 1% carrageenan.)
0.3mLdistilledwater.Themixturewasincubatedat98◦Cfor
1h. Upon cooling, 5mL of n-butanol/pyridine (15:1) was
added. The mixture was vortexed for 1min and centrifuged
for 30min at 4000rpm. The supernatant absorbance was
measured at 532nm. A standard curve was generated using
1,1,3,3-tetramethoxypropane. All samples were measured in
triplicate. The results were expressed as nmol MDA per gram
wet tissue (nmol/g tissue).
2.7. Statistical Analyses. Data for acute and chronic inﬂam-
mation models and acute nociceptive thresholds model were
subjected to one-way analysis of variance (ANOVA) using
SPSS 13.0 software. Only the data for propranolol examina-
tion were subjected to “two-independent-sample t-test.” Dif-
ferences among the groups were obtained using the LSD
option and were considered signiﬁcant at P<0.05. A sta-
tistical analysis of oxidative enzymes was carried out using
one-way ANOVA followed by Duncan’s multiple range test
(DMRT)usingtheSPSSsoftwarepackage,version13.00,and
were considered signiﬁcant at P<0.05. All the results were
expressed as mean ± SE.
3. Results
3.1. Carrageenan-Induced Paw Edema in Rats. As seen in
Table 1, both doses of salbutamol and indomethacin signiﬁ-
cantly decreased carrageenan-induced paw edema formation
in rats. The anti-inﬂammatory eﬀects of 1mg/kg dose of
salbutamol were determined as 43.9%, 43.4%, 44%, and
37.5%, respectively, for the 1st, 2nd, 3rd, and 4th hours.
For the same hours, a 2mg/kg dose of salbutamol produced
44.6%, 48.1%, 48.5%, and 48.8% anti-inﬂammatory eﬀects,
respectively. In comparison, the anti-inﬂammatory eﬀects of
indomethacin were 27.7%, 40.3%, 42.7%, and 48.4%, res-
pectively, for the same time intervals.
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Figure 1: Eﬀects of combination of salbutamol (2mg/kg) and
propranolol (40mg/kg) (PROP + SAL) on carrageenan-induced
inﬂammatory paw volume in rats. CONT: control.
In the second series of our experiments we determined
that 40mg/kg dose of propranolol reversed the anti-inﬂam-
matory eﬀect of salbutamol (2mg/kg). Namely, salbutamol
could not inhibit inﬂammation formation when β-adrener-
gic receptors were blocked (Figure 1).
3.2. Carrageenan-Induced Paw-Hyperalgesia in Rats. As seen
in Table 2, both doses of salbutamol and indomethacin sig-
niﬁcantly prevented the carrageenan-induced decrease in
nociceptive thresholds in rat paws till the 3rd hour of car-
rageenan injection. In the 1st hour after carrageenan injec-
tion, the 1 and 2mg doses of salbutamol and 25mg/kg dose
of indomethacin produced 57%, 61.1%, and 71.6% analgesic
eﬀects, respectively. The same doses of the drugs produced
44.2%, 47.8%, and 55% analgesic eﬀects in the 2nd hour.Mediators of Inﬂammation 5
Table 3: Eﬀects of salbutamol and indomethacin cotton pellet granuloma test.
Drugs Dose (mg/kg) Initial weight of the
cotton pellets (mg)
Wet weight of cotton pellets that were
removed after 8 days (mg)
Inhibition in granuloma
formation (%)
Salbutamol 1 7 ±1 94.0 ± 4.1∗∗ 44.3
Salbutamol 2 7 ±1 116.7 ± 3.0∗ 30.8
Indomethacin 5 7 ±1 41.3 ± 3.4∗∗ 75.5
Control — 7 ±1 168.7 ± 4.3 —
∗Signiﬁcant at P<0.05 when compared to control, ∗∗signiﬁcant at P<0.01 when compared to control.
In the3rd hour the analgesiceﬀectsof salbutamolwere lower
than those in 1st and 2nd hours (36.9% for 1mg/kg dose
and 42.9% for 2mg/kg dose). In the 3rd hour, indomethacin
produced a 58.5% analgesic eﬀect.
3.3. Cotton Pellet Test in Rats. On the 8th day, mean weights
of moist pellets removed from the rat groups administered
salbutamol (1 and 2mg/kg) and indomethacin (5mg/kg)
and the control group were 94.0 ± 4.1mg, 116.7 ± 3.0mg,
41.3 ± 3.4mg, and 168.7 ± 4.3mg, respectively. According to
these results, the eﬀects of salbutamol 1mg/kg, salbutamol
2mg/kg, and indomethacin on chronic inﬂammation were
evaluatedas44.3%,30.8%,and75.5%,respectively(Table 3).
3.4. Biochemical Analyses. Carrageenan injection to rat paws
produced a signiﬁcant increase in MPO activity and LPO
level. However both doses of salbutamol signiﬁcantly pre-
vented the carrageenan induced increase in theses param-
eters (P<0.05). Indomethacin administration also signi-
ﬁcantly decreased (P<0.05) the MPO activity and LPO level
when compared to control group that received carrageenan
alone. The 2mg/kg dose of salbutamol was more eﬀective
in decreasing MPO activity and LPO level than the 1mg/kg
dose of salbutamol or the 25mg/kg dose of indomethacin
(Figures 3 and 4). Carrageenan treatment resulted in a sig-
niﬁcant decrease in the activity of SOD and level of GSH,
which were increased by salbutamol and indomethacin
administration (P<0.05). The 2mg/kg dose of salbutamol
was the best of the three drug treatments in terms of in-
creasing SOD activity and GSH level (Figures 2, 3, 4,a n d5).
4. Discussion
This study investigated the protective eﬀect of salbutamol,
a β-2 adrenergic receptor agonist drug used in bronchial
asthma,onacute(carrageenan-induced)andchronic(cotton
pellet induced) inﬂammation models and on a carrageenan-
induced nociception model. Tissue levels and activities of
LPO,GSH,MPO,andSODwereusedtoestimateantioxidant
eﬀects.
Our study demonstrated that both doses of salbutamol
(1 and 2mg/kg) eﬀectively reduced the acute inﬂammation
and inﬂammatory nociception associated with carrageenan
injection. Carrageenan application is known to produce an
inﬂammatory response that peaks at three hours, resulting in
hyperalgesia [50]. In this experimental inﬂammation model,
levels of inﬂammatory mediators have been reported to
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Figure 2: Eﬀects of salbutamol (SAL) and indomethacin (IND)
on superoxide dismutase (SOD) activity in carrageenan-injected
paw tissues. Means in the same column by the same letter are
not signiﬁcantly diﬀerent and the means in the same column by
diﬀerent letters demonstrate signiﬁcant diﬀerences between the
groups according to the Duncan test (α = 0.05). In the above ﬁgure,
all columns have diﬀerent letters. This demonstrates that values in
these columns are statistically diﬀerent from each other.
increase fourfold between the 1st and 3rd hours after a car-
rageenan injection and then to remain high for several hours
thereafter [51]. In the present study, the preventive eﬀect of
salbutamol on inﬂammation and related nociception forma-
tion was comparable with that of indomethacin, a potent
anti-inﬂammatory drug. Both salbutamol and indomethacin
exerted anti-inﬂammatory and analgesic eﬀects; however, it
is known that indomethacin has quite harmful eﬀects on
stomach tissue such as ulcer, perforation, and even bleeding.
The ratio of occurrence for the side eﬀects is approximately
35–50%,andasaresultofpresentsideeﬀects20%ofpatients
are forced to stop indomethacin therapy [52]. Long-acting
beta agonists have also side eﬀects in high doses on cardio-
vascular system by activating sympathetic system. However,
these side eﬀects are not severe in salbutamol usage because
it has a short half-life [53]. So salbutamol may be safer than
indomethacin in inﬂammation treatment.
Salbutamol selectively activates the β-2 adrenergic recep-
tors and is clinically used for treatment of acute and chronic
asthma [19]. In our previous studies, we suggested that β-2
adrenergic receptors may play a role in the suppression of
inﬂammation as stimulation of these receptors would pro-
duce anti-inﬂammatory and, consequently, analgesic eﬀects
[10, 11]. There is also some evidence that catecholamines
suppress immune cell functions in inﬂammatory tissues and
that they produce this suppressive eﬀect via activation of6 Mediators of Inﬂammation
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Figure 3: Eﬀects of salbutamol (SAL) and indomethacin (IND) on
myeloperoxidase (MPO) activity in carrageenan-injected paw tis-
sues. Means in the same column by the same letter are not signif-
icantly diﬀerent and the means in the same column by diﬀerent
letters demonstrate signiﬁcant diﬀerences between the groups
according to the Duncan test (α = 0.0 5 ) .I nt h ea b o v eﬁ g u r e ,t h e
letter for the means in SAL-1 and IND columns is the same: “c.”
This demonstrates that values in these lines are not statistically
diﬀerent from each other. However, the lines with the letter “c” are
statistically signiﬁcant from the lines with the letters “a,” “b,” and
“d.”
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Figure 4: Eﬀects of salbutamol (SAL) and indomethacin (IND) on
lipid peroxidation (LPO) level in carrageenan-injected paw tissues.
Means in the same column by the same letter are not signiﬁcantly
diﬀerent and the means in the same column by diﬀerent letters
demonstrates signiﬁcant diﬀerences between the groups according
to the Duncan test (α = 0.05). In the above ﬁgure, all columns have
diﬀerent letters. This demonstrates that values in these columns are
statistically diﬀerent from each other.
β-adrenergic receptors [12]. In another study, adrenergic
agents were shown to suppress the immune response (the
production of TNF-α) via the direct stimulation of β-ad-
renergic receptors on inﬂammatory immune cells [13]. Also
some recent studies suggested that β-2 adrenergic receptor
activation can inhibit nociception and inﬂammation [16–
18]. These previous reports concerning the roles of β-2
adrenergic receptors in inﬂammatory conditions support a
preventive role for salbutamol in inﬂammatory and related
hyperalgesic conditions, as postulated in the present study.
The eﬀects of salbutamol and indomethacin on chronic
phasesofinﬂammationinthecottonpelletgranulomatestof
intactratswerealsosupportiveofthishypothesis.Thecotton
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Figure 5: Eﬀects of salbutamol (SAL) and indometacin (IND)
on reduced glutathione (GSH) level in carrageenan-injected-paw
tissues. Means in the same column by the same letter are not sig-
niﬁcantly diﬀerent and the means in the same column by diﬀerent
letters demonstrate signiﬁcant diﬀerences between the groups
according to the Duncan test (α = 0.05). In the above ﬁgure, the
letterforthemeansinSAL-2,IND,andhealthycolumnsisthesame:
“c.” This demonstrates that values in these lines are not statistically
diﬀerent from each other. However, the lines with the letter “c” are
statistically signiﬁcant from the lines with the letters “a” and “b.”
pellet test is a chronic inﬂammation model used for eval-
uating the antiproliferative eﬀects of drugs [43]. Both doses
of salbutamol signiﬁcantly decreased the weight of cotton
pellets when compared to the control. A short time after the
initiationofacuteinﬂammation,proliferativecellsdeveloped
and inﬂammation became chronic. Prevention of collagen
ﬁber formation and suppression of mucopolysaccharides are
indicators of the antiproliferative eﬀect of anti-inﬂammatory
agents [54]. Monocyte inﬁltration and ﬁbroblast prolifera-
tion occur in chronic inﬂammation instead of neutrophil
inﬁltration and exudation [44]. Activated monocyte-macro-
phages are blood cells that have antitumor and antimicrobial
functions in addition to phagocytotic functions against
pathogens [55]. Salbutamol selectively binds to and activates
β-2-adrenoceptors, which are molecules on the surface of
many cells, such as CD4 cells, leukocytes, monocytes, macro-
phages, and Langerhans cells [20–22]. The binding of a β-2
receptor agonist to these cells results in stimulation of the
receptor and inhibition of expression of inﬂammatory genes.
This prevents the production of proinﬂammatory cytokines,
such as interleukin-2 and interferon-γ [24, 56], and eﬀec-
tively suppresses inﬂammation. Therefore, the primary ef-
fects of salbutamol on the chronic phase of inﬂammation
may be associated with its eﬀects on the β-2 adrenergic
receptors located on the monocytes and macrophages that
comprise the basic components of chronic inﬂammation. In
contrast to our hypothesis Oliveira et al. and Pelegrini-da-
Silva et al. suggested that serotonin-induced inﬂammatory
hyperalgesiaandtemporomandibularjointinﬂammationare
mediatedbysympatheticamines-dependentmechanismthat
involves the activation of peripheral β-2 adrenergic receptors
[15, 57]. However, expression of β-2 adrenergic receptors
within the nociceptive system suggested their potential
implication in nociception and pain and studies suggesting
that β-2 adrenergic receptor agonists may potentially oﬀerMediators of Inﬂammation 7
analternativetherapytoantidepressantdrugsforthechronic
treatment of neuropathic pain [17, 18, 58]. These data bring
up such a dilemma: “Are central β2 adrenergic receptors
involved in the analgesic eﬀects of salbutamol or is it only
consequence of the reduction in the inﬂammatory pro-
cess?”. In this point, previous studies which claimed that
surgical stress induces sympathetically activated release of
endogenousopioidsfrominﬂammatorycellsandsubsequent
analgesia via activation of peripheral opioid receptors [59]
make us hypothesize that salbutamol shows its antihyperal-
gesic eﬀects by inhibition of inﬂammation and peripheral
sympathetic activation. Also in our study propranolol, a
β-adrenergic receptor antagonist, administration reversed
the anti-inﬂammatory eﬀects of salbutamol suggesting that
salbutamol mediated its anti-inﬂammatory eﬀects via β-2
adrenergic receptors. However, future studies comparing
eﬀects of both peripheral and central β-2 adrenergic recep-
tors are required for a better understanding.
An acute inﬂammatory process is comprised of inﬂam-
mation mediators including neutrophil-derived ROS, nitric
oxide [60, 61] prostaglandins, and cytokines [62]. Also neu-
trophil accumulation liberated proinﬂammatory mediators
such as cytokines, including TNF-α and IL-1β, are consid-
ered to be proinﬂammatory agents that stimulate the cellular
chemotaxis and serve to furtherincrease tissue inﬂammation
[29]. ROS play an important role in the pathogenesis of
many diseases, such as rheumatoid arthritis, local or sys-
temic inﬂammatory disorders, ischemia-reperfusion injury,
atherosclerosis, cancer, and respiratory distress syndrome
[61, 63–65]. In respiratory diseases such as asthma, selective
stimulation of β-2 adrenergic receptors results in NO pro-
duction [66], which suggests that salbutamol produces its
bronchodilator eﬀects by stimulating β-2 adrenergic recep-
tors, resulting in activated NO production [67–69]. Salbu-
tamol also inhibits superoxide generation and peroxidase
release from stimulated human granulocytes [24]. However,
the eﬀects of salbutamol on other parameters related to
oxidativestressininﬂammatoryconditionshavenotyetbeen
evaluated in detail in inﬂammatory conditions.
Ourstudyinvestigatedeﬀectsofsalbutamolonsomeoxi-
dative parameters such as MPO and SOD activities and LPO
and GSH levels during the acute phase of inﬂammation. In
inﬂamed tissues, activities of MPO and LPO are signiﬁcantly
increased. In the present case, both doses of salbutamol and
indomethacin decreased the carrageenan-induced aggrava-
tion of MPO and LPO. MPO is an enzyme found primarily
in azurophilic granules of neutrophils and is used as a
marker for tissue neutrophil content. Its inhibition implies
the presence of anti-inﬂammatory activity [47, 70]. Tissue
MPO activity is a sensitive and speciﬁc marker for acute
inﬂammation and reﬂects polymorphonuclear cell inﬁltra-
tion of the parenchyma. In accordance with the literature
[71, 72], MPO activity in the present study signiﬁcantly in-
creased in the paw at the 4th hour after carrageenan injec-
tion when compared to healthy control rats. A variety of
anti-inﬂammatory drugs (e.g., diclofenac, indomethacin,
naproxen, piroxicam, and tenoxicam) have been shown to
similarly depress the increases in myeloperoxidase activity
during inﬂammation [73, 74].
Lipid peroxidation has been reported to increase in
inﬂammatory conditions [38, 75, 76]. As a marker of oxi-
dative damage, lipid peroxidation indicates changes in mem-
brane ﬂuidity and permeability and thus increases in rates of
protein degradation, which will eventually lead to cell lysis
[77]. Increased concentrations of LPO in tissue have been
reported in the carrageenan-induced inﬂammation model
[78]. In our study, LPO content was high in carrageenan-
induced inﬂamed paws; however, salbutamol administration
prevented this increase in the LPO content of the paws.
Tissue damage related to oxidative stress can be reversed
via SOD enzyme and GSH. The action of these parameters
limits the cytotoxic eﬀe c t so ft o x i cf r e er a d i c a l s[ 79, 80]. In
our study, salbutamol also signiﬁcantly increased both GSH
content and SOD activity in inﬂammatory paws compared
to control paws. In many laboratory models and in a few
clinical trials, SOD has proven to be therapeutically useful in
protecting injured tissues (e.g., by ischemia, inﬂammation,
hyperoxia, etc.) from one of these active oxygen species, the
superoxide radical [80]. Preventive eﬀects of salbutamol on
superoxide generation and peroxidase release from stimu-
lated human granulocytes [24] also supports our results.
GSH has pleiotropic roles including the maintenance of cells
in a reduced state, serving as an electron donor for certain
antioxidative enzymes (e.g., glutathione peroxidase), and in
the formation of conjugates with some harmful endogenous
and xenobiotic compounds via catalysis of glutathione s-
transferase [79]; thus, the ameliorating eﬀects of salbutamol
on GSH demonstrated a further beneﬁcial eﬀect of its admi-
nistration. These results may also suggest that salbutamol
attenuated the carrageenan-induced inﬂammation by pre-
venting oxidative stress.
In conclusion, salbutamol, a bronchodilator agent used
for asthma treatment, can eﬀectively decrease both acute
(carrageenan-induced) and chronic (cotton-pellet-induced)
inﬂammation and propranolol reversed the anti-inﬂamma-
tory eﬀects of salbutamol. Stimulation of β-2 adrenergic
receptors may be the underlying mechanism responsible for
the observed anti-inﬂammatory eﬀects. Since inﬂammation
also takes part in asthma etiopathology, these observations
may be of clinical relevance. Salbutamol also exerted sig-
niﬁcant antioxidative eﬀects, which could at least partially
explain the mechanism underlying its anti-inﬂammatory
eﬀects. This study may also shed light on the roles of β-2
adrenergic receptors in inﬂammatory and algesic conditions.
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